Fate Therapeutics
Market Cap
US$2.5b
Last Updated
2020/05/31 05:45 UTC
Data Sources
Company Financials +
Executive Summary
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Similar Companies
Share Price & News
How has Fate Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FATE's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-7.9%
FATE
0.5%
US Biotechs
3.0%
US Market
1 Year Return
68.2%
FATE
27.3%
US Biotechs
9.9%
US Market
Return vs Industry: FATE exceeded the US Biotechs industry which returned 27.6% over the past year.
Return vs Market: FATE exceeded the US Market which returned 9.5% over the past year.
Shareholder returns
| FATE | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.9% | 0.5% | 3.0% |
| 30 Day | 22.0% | 9.2% | 8.2% |
| 90 Day | 4.6% | 12.8% | 0.4% |
| 1 Year | 68.2%68.2% | 28.6%27.3% | 12.4%9.9% |
| 3 Year | 813.5%813.5% | 34.7%30.2% | 31.0%22.3% |
| 5 Year | 414.8%414.8% | -1.9%-7.8% | 58.1%40.3% |
Price Volatility Vs. Market
How volatile is Fate Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Industry Analysts Just Made A Sizeable Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts1 month ago | Simply Wall St
Did The Underlying Business Drive Fate Therapeutics' (NASDAQ:FATE) Lovely 576% Share Price Gain?1 month ago | Simply Wall St
Need To Know: Analysts Are Much More Bullish On Fate Therapeutics, Inc. (NASDAQ:FATE) RevenuesValuation
Is Fate Therapeutics undervalued compared to its fair value and its price relative to the market?
11.24x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: FATE ($32.43) is trading above our estimate of fair value ($3.28)
Significantly Below Fair Value: FATE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: FATE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: FATE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FATE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FATE is overvalued based on its PB Ratio (11.2x) compared to the US Biotechs industry average (3.6x).
Next Steps
Future Growth
How is Fate Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
9.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FATE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FATE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FATE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FATE's revenue (81.4% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: FATE's revenue (81.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FATE is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Fate Therapeutics performed over the past 5 years?
-29.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FATE is currently unprofitable.
Growing Profit Margin: FATE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FATE is unprofitable, and losses have increased over the past 5 years at a rate of -29.5% per year.
Accelerating Growth: Unable to compare FATE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FATE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: FATE has a negative Return on Equity (-51.05%), as it is currently unprofitable.
Next Steps
Financial Health
How is Fate Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: FATE's short term assets ($208.2M) exceed its short term liabilities ($24.9M).
Long Term Liabilities: FATE's short term assets ($208.2M) exceed its long term liabilities ($77.7M).
Debt to Equity History and Analysis
Debt Level: FATE is debt free.
Reducing Debt: FATE has no debt compared to 5 years ago when its debt to equity ratio was 89.8%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FATE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FATE has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 27.1% each year.
Next Steps
Dividend
What is Fate Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FATE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FATE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FATE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FATE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FATE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average management tenure
CEO
J. Wolchko (49yo)
4.42yrs
Tenure
US$10,720,955
Compensation
Mr. J. Scott Wolchko is the Founder of Fate Therapeutics, Inc. and has been its Chief Executive Officer and President since December 1, 2015. Mr. Wolchko served as Principal Financial Officer and Principal ...
CEO Compensation Analysis
Compensation vs Market: J.'s total compensation ($USD10.72M) is above average for companies of similar size in the US market ($USD5.91M).
Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 4.42yrs | US$10.72m | 0.13% $3.4m | |
| Chief Scientific Officer | 5yrs | US$2.82m | 0.11% $2.9m | |
| General Counsel & Corporate Secretary | 4.58yrs | US$2.82m | 0.057% $1.4m | |
| Chief Development Officer | 2.33yrs | US$2.82m | 0.041% $1.0m | |
| Senior Vice President of Technical Operations | 1.58yrs | no data | no data | |
| Senior Vice President of Corporate Development | 2.58yrs | no data | no data | |
| Senior Vice President of Clinical Translation | 1.17yrs | no data | no data | |
| Senior Vice President of Clinical Development | 0.33yr | no data | no data |
2.5yrs
Average Tenure
47.5yo
Average Age
Experienced Management: FATE's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 4.42yrs | US$10.72m | 0.13% $3.4m | |
| Independent Chairman | 8.42yrs | US$277.14k | 0.78% $19.7m | |
| Independent Vice Chairman of the Board | 8.42yrs | US$245.98k | 0.20% $5.1m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 10yrs | no data | no data | |
| Member of Scientific Advisory Board | 10yrs | no data | no data | |
| Independent Director | 6.75yrs | US$250.95k | 0.073% $1.8m | |
| Member of Scientific Advisory Board | 10yrs | no data | no data | |
| Member of Scientific Advisory Board | 10yrs | no data | no data |
9.2yrs
Average Tenure
64.5yo
Average Age
Experienced Board: FATE's board of directors are considered experienced (9.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.2%.
Top Shareholders
Company Information
Fate Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Fate Therapeutics, Inc.
- Ticker: FATE
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.520b
- Shares outstanding: 77.69m
- Website: https://www.fatetherapeutics.com
Number of Employees
Location
- Fate Therapeutics, Inc.
- 3535 General Atomics Court
- Suite 200
- San Diego
- California
- 92121
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| FATE | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Oct 2013 |
| F6T | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 2013 |
Biography
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company’s NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/31 05:45 |
| End of Day Share Price | 2020/05/29 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.